62Zou J, Pyykko I, Bjelke B, Bretlau P, Tayamaga T: Endolympahtic Hydrops is Caused by Increased Porosity of Stria Vascularis? Barany Society Meeting. Uppsala, Sweden, 2000.
63Niyazov DM, Andrews JC, Strelioff D, Sinha S, Lufkin R: Diagnosis of endolymphatic hydrops in vivo with magnetic resonance imaging. Otol Neurotol 2001;22:813–817.
64Zou J, Pyykko I, Bjelke B, Dastidar P, Toppila E: Communication between the perilymphatic scalae and spiral ligament visualized by in vivo MRI. Audiol Neurootol 2005;10:145–152.
65Nakashima T, Naganawa S, Sugiura M, Teranishi M, Sone M, Hayashi H, et al: Visualization of endolymphatic hydrops in patients with Meniere’s disease. Laryngoscope 2007;117:415–420.
66Pyykko I, Zou J, Poe D, Nakashima T, Naganawa S: Magnetic resonance imaging of the inner ear in Meniere’s disease. Otolaryngol Clin North Am 2010;43:1059–1080.
67Gurkov R, Flatz W, Louza J, Strupp M, Krause E: In vivo visualization of endolyphatic hydrops in patients with Meniere’s disease: correlation with audiovestibular function. Eur Arch Otorhinolaryngol 2011;268:1743–1748.
68Naganawa S, Yamazaki M, Kawai H, Bokura K, Iida T, Sone M, et al: MR imaging of Meniere’s disease after combined intratympanic and intravenous injection of gadolinium using HYDROPS2. Magn Reson Med Sci 2014;13:133–137.
69Nakashima T, Sone M, Teranishi M, Yoshida T, Terasaki H, Kondo M, et al: A perspective from magnetic resonance imaging findings of the inner ear: Relationships among cerebrospinal, ocular and inner ear fluids. Auris Nasus Larynx 2012;39:345–355.
70Nakashima T, Naganawa S, Pyykko I, Gibson WP, Sone M, Nakata S, et al: Grading of endolymphatic hydrops using magnetic resonance imaging. Acta Otolaryngol Suppl 2009;560:5–8.
71Pyykko I, Nakashima T, Yoshida T, Zou J, Naganawa S: Meniere’s disease: a reappraisal supported by a variable latency of symptoms and the MRI visualisation of endolymphatic hydrops. BMJ Open 2013;3:pii:e001555.
72Gurkov R, Flatz W, Louza J, Strupp M, Ertl-Wagner B, Krause E: In vivo visualized endolymphatic hydrops and inner ear functions in patients with electrocochleographically confirmed Meniere’s disease. Otol Neurotol 2012;33:1040–1045.
73Liu F, Huang W, Wang Z, Chen Q, Liu X, Li S, et al: Noninvasive evaluation of endolymphatic space in healthy volunteers using magnetic resonance imaging. Acta Otolaryngol 2011;131:247–257.
74Counter SA, Bjelke B, Borg E, Klason T, Chen Z, Duan ML: Magnetic resonance imaging of the membranous labyrinth during in vivo gadolinium (Gd-DTPA-BMA) uptake in the normal and lesioned cochlea. Neuroreport 2000;11:3979–3983.
75Zou J, Pyykko I, Counter SA, Klason T, Bretlau P, Bjelke B: In vivo observation of dynamic perilymph formation using 4.7 T MRI with gadolinium as a tracer. Acta Otolaryngol 2003;123:910–915.
76Zou J, Zhang W, Poe D, Zhang Y, Ramadan UA, Pyykko I: Differential passage of gadolinium through the mouse inner ear barriers evaluated with 4.7T MRI. Hear Res 2010;259:36–43.
77Zou J, Yoshida T, Ramadan UA, Pyykko I: Dynamic enhancement of the rat inner ear after ultra-small-volume administration of Gd-DOTA to the medial wall of the middle ear cavity. ORL J Otorhinolaryngol Relat Spec 2011;73:275–281.
78Zou J, Pyykko I: Enhanced oval window and blocked round window passages for middle-inner ear transportation of gadolinium in guinea pigs with a perforated round window membrane. Eur Arch Otorhinolaryngol 2015;272:303–309.
79Kaasinen S, Pyykko I, Ishizaki H, Aalto H: Intratympanic gentamicin in Meniere’s disease. Acta Otolaryngol 1998;118:294–298.
80Eklund S, Pyykko I, Aalto H, Ishizaki H, Vasama JP: Effect of intratympanic gentamicin on hearing and tinnitus in Meniere’s disease. Am J Otol 1999;20:350–356.
81Louza JP, Flatz W, Krause E, Gurkov R: Short-term audiologic effect of intratympanic gadolinium contrast agent application in patients with Meniere’s disease. Am J Otolaryngol 2012;33:533–537.
82Louza J, Krause E, Gurkov R: Audiologic evaluation of Meniere’s disease patients one day and one week after intratympanic application of gadolinium contrast agent: our experience in sixty-five patients. Clin Otolaryngol 2013;38:262–266.
83Louza J, Krause E, Gurkov R: Hearing function after intratympanic application of gadolinium-based contrast agent: a long-term evaluation. Laryngoscope 2015;125:2366–2370.
84Yoshioka M, Naganawa S, Sone M, Nakata S, Teranishi M, Nakashima T: Individual differences in the permeability of the round window: evaluating the movement of intratympanic gadolinium into the inner ear. Otol Neurotol 2009;30:645–648.
85Naganawa S, Yamazaki M, Kawai H, Bokura K, Sone M, Nakashima T: Imaging of Meniere’s disease after intravenous administration of single-dose gadodiamide: utility of subtraction images with different inversion time. Magn Reson Med Sci 2012;11:213–219.
86Wu Q, Dai C, Zhao M, Sha Y: The correlation between symptoms of definite Meniere’s disease and endolymphatic hydrops visualized by magnetic resonance imaging. Laryngoscope 2016;126:974–979.
87Yamazaki M, Naganawa S, Tagaya M, Kawai H, Ikeda M, Sone M, et al: Comparison of contrast effect on the cochlear perilymph after intratympanic and intravenous gadolinium injection. AJNR Am J Neuroradiol 2012;33:773–778.
88Naganawa S, Yamazaki M, Kawai H, Bokura K, Sone M, Nakashima T: Visualization of endolymphatic hydrops in Meniere’s disease with single-dose intravenous gadolinium-based contrast media using heavily T(2)-weighted 3D-FLAIR. Magn Reson Med Sci 2010;9:237–242.
89Attye A, Dumas G, Tropres I, Roustit M, Karkas